Relative Bioavailability of CE-Iohexol (Captisol-enabled ™ Iohexol) Injection and Omnipaque™ Injection
Conditions:   Contrast-induced Nephropathy;   Coronary Angiography Interventions:   Other: Omnipaque™ (iohexol) Injection;   Other: CE-Iohexol Sponsors:   CyDex Pharmaceuticals, Inc.;   Ligand Pharmaceuticals;   Syneos Health Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2019 Category: Research Source Type: clinical trials

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin
Condition:   Drug-drug Interaction Interventions:   Drug: Tucatinib;   Drug: Metformin;   Drug: Iohexol Sponsor:   Seattle Genetics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2019 Category: Research Source Type: clinical trials

Description of the Evolution of Plasma and Urinary Concentrations of Iohexol in a Cirrhotic Patient Population
Condition:   Cirrhosis Renal Intervention:   Drug: Iohexol Inj 300 MG/ML Sponsor:   University Hospital, Limoges Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2018 Category: Research Source Type: clinical trials

EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) study: study protocol for a randomized controlled trial
This study aims to assess the effect of MRA administration in the early phase of kidney transplantation (KT) among recipients of ECD grafts on mid-term graft function.Methods/designThis is a multicenter, double-blind, placebo-controlled, randomized clinical trial. Patients on hemodialysis and undergoing a single or a dual KT from an ECD will be eligible for inclusion. We plan to randomize 132 patients. Included patients will be randomized (1:1) to receive either eplerenone 25  mg every 12 h during 4 days (the first dose being administered just prior to KT) or placebo. The primary outcome is graft function at...
Source: Trials - October 30, 2018 Category: Research Source Type: clinical trials

Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
Condition:   Hypothyroidism Interventions:   Drug: Iohexol;   Drug: Iodixanol;   Drug: Iopromide Sponsors:   GE Healthcare;   Bayer;   Duke Clinical Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2018 Category: Research Source Type: clinical trials

A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants
Condition:   Renal Insufficiency Interventions:   Drug: Lanabecestat;   Drug: Iohexol Sponsors:   Eli Lilly and Company;   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 4, 2018 Category: Research Source Type: clinical trials